Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPIRESCUE: Nivolumab and ipilimumab in dMMR/MSI metastatic colorectal cancer resistant to anti-PD1
2021-005146-15Phase 2Active
- Sponsor
- GERCOR
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in colorectal cancer (CRC), sponsored by GERCOR. Primary endpoint: Objective response rate at 24 weeks. Started Oct 2021; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2021-005146-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005146-15.